British biotech faces a funding battle in race with the US

in Portfolio News

Quell Therapeutics, an SV portfolio company which recently entered into an exclusive option and license agreement with AZ receiving $85m upfront and a potential further $2bn for development and commercialisation milestones has been interviewed by The Times

View the article
Investing in Women Code Logo

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.